S 3311
118th Congress
Senate
Health
Buy American requirements
Child health
Congressional oversight
Drug therapy
Emergency medical services and trauma care
Health care costs and insurance
Health technology, devices, supplies
Infectious and parasitic diseases
Manufacturing
Medicaid
Medicare
Poverty and welfare assistance
Prescription drugs
Public contracts and procurement
American Made Pharmaceuticals Act of 2023
Everywhere this bill has been
3 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Jul 25, 2024
Committee on Banking, Housing, and Urban Affairs. Hearings held. Hearings printed: S.Hrg. 118-655.
Nov 15, 2023
Read twice and referred to the Committee on Finance.
Nov 15, 2023
Introduced in Senate
Plain-English summary
American Made Pharmaceuticals Act of 2023
This bill requires the Centers for Medicare & Medicaid Services to conduct a demonstration program that gives preference to domestically manufactured drugs under Medicare, Medicaid, and the Children's Health Insurance Program (CHIP).
The program must be conducted in at least eight states and for at least seven years. Applicable drugs include critical drugs that are needed to respond to a public health emergency and that have a vulnerable global supply chain. Preference may take the form of reduced cost-sharing, preferential treatment on formularies, bonus payments, and other specified methods.
What's happening now
Committee on Banking, Housing, and Urban Affairs. Hearings held. Hearings printed: S.Hrg. 118-655.
Committees of jurisdiction
2